NCT00174629已完成3 期
Open-Label, Cooperative, Randomized, Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype (ERCC1 Over-Expression) in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 449
- 试验地点
- 1
- 主要终点
- Overall response rate (complete plus partial responses) between the genotypic group and the control group using an intent-to-treat analysis.
研究概览
简要总结
Primary Objective:
- To compare response rate between genotypic groups and control group.
Secondary Objective:
- To determine the safety, time to treatment failure and survival in control and genotypic arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be/have:
- •histologically confirmed non-small cell lung cancer (squamous cell carcinoma, large cells or adenocarcinoma; it is recommended to provide the full paraffin-embedded block or at least 5 5 sections obtained from the primary tumor, recurrence or metastasis, not stained, fixed in formalin/embedded in paraffin, mounted on slides (10 micron sections), as well as two serum samples in two 10-ml tubes and two blood samples (see appendix X);
- •unresectable metastatic (stage IV or IIIB malignant pleural effusion) NSCLC;
- •WHO performance status < 2;
- •Adequate bone marrow, hepatic and renal functions, assessed during the previous 14 days, that should be shown by the following characteristics:
- •hemoglobin > or = 10g/dl and no blood cell transfusion within the previous 2 weeks;
- •absolute neutrophil count > 2.0 10^9 cells/l;
- •platelet count > or = 100.10^9 cells/l;
- •no evidence of myelodysplastic syndrome or abnormal bone marrow reserve;
- •creatinine < or = 1.5 x UNL or creatinine clearance > or = 60 ml/min (real or calculated);
- •total bilirubin < or = UNL;
- •ASAT (SGOT) and/or ALAT (SGPT) < or = 1.5 x UNL;
- •alkaline phosphatases < or = 5 x UNL;
- •serum calcium < or = 1.1 x UNL;
- •at least one measurable lesion;
- •previous surgery intervention (more than 30 days before inclusion in the study) is allowed but metastatic disease must be demonstrated;
- •previous radiotherapy is allowed if:
- •less or equal to 10% of bone marrow has been irradiated
- •end of radiotherapy 21 days or more prior to inclusion in the study;
- •patient has fully recovered from all toxic effects;
- •at least one of the measurable target lesions for evaluation of tumor response has not been irradiated;
- •the patient must be accessible for treatment and follow-up. The patient entered into this trial must be treated and followed up at the participating center;
- •life expectancy > or = 12 weeks;
- •The initial diagnostic procedures should be performed during the 4 weeks prior to the randomization.
排除标准
- •pregnant or lactating women (women of childbearing potential must use adequate contraception);
- •prior systemic chemotherapy or immunotherapy for NSCLC, even as neoadjuvant or adjuvant therapy;
- •prior malignancies, except cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with non-evidence of disease for at least 5 years;
- •history or clinical symptomatic brain or leptomeningeal metastases;
- •current peripheral neuropathy and neurohearing > or = NCIC-CTG grade 2 except if due to trauma;
- •other serious illness or medical condition, including:
- •congestive heart disease; prior myocardial infarction within 6 months;
- •history of significant neurologic or psychiatric disorders that would inhibit their understanding and giving of informed consent;
- •infection requiring I.V. antibiotics and tuberculosis under treatment ongoing at study entry;
- •untreated superior vena cava syndrome;
- •active peptic ulcer; unstable diabetes mellitus or other contraindication to high dose corticotherapy such as herpes, herpes zoster, cirrhosis;
- •hypercalcemia requiring therapy;
- •preexisting ascitis and/or clinical significant pericardial effusion;
- •patients whose lesion(s) are assessable only by radionuclide scan;
- •history of allergy to drugs containing the excipient TWEEN 80®;
- •concurrent treatment with other investigational drugs;
- •participation in a clinical trial of one or more investigational agents (i.e. antibiotic) or devices within 30 days of study entry.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
1
Experimental
干预措施: docetaxel/gemcitabine (Drug)
2
Active Comparator
干预措施: Docetaxel/DDP (Drug)
结局指标
主要结局
Overall response rate (complete plus partial responses) between the genotypic group and the control group using an intent-to-treat analysis.
次要结局
- Time to treatment failure and survival(calculated from the registration date until progression or death, respectively)
- Clinical and laboratory toxicities graded according to NCIC-CTG Expanded Common Toxicity Criteria.(before each cycle)
- Adverse events not reported in NCIC-CTG Expanded Common Toxicity Criteria will be graded as mild, moderate, severe, and life threatening.(Throughout the study)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLCAdvanced Non-squamous NSCLCNCT00369070Amgen186
已完成
2 期
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaMelanomaNCT00289640Bristol-Myers Squibb210
终止
3 期
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast CancerBreast NeoplasmNCT00251095Achieve Life Sciences821
已完成
不适用
The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy VolunteersInteractionNCT01482117Inje University28
终止
2 期
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.High Risk MDSNCT02159040Novartis Pharmaceuticals1